Formulated for breast cancer to target estrogen receptors and support malignant cell inhibition.
Mechanism of Action
Tamoxifen is a selective estrogen receptor modulator. In breast tissue, it competitively inhibits estrogen binding to its receptor, blocking the stimulatory effect of estrogen on tumor cell growth.
Route of Administration
Oral
Onset Time
4–8 weeks
Duration
5–7 days (half-life)
Contraindications
Hypersensitivity to tamoxifen, Concurrent warfarin therapy (for risk reduction), History of deep vein thrombosis
Severe Adverse Events
Endometrial cancer, Pulmonary embolism, Stroke — requires immediate medical attention
Information related to Tamoxifen is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
